Pyruvate kinase: Function, regulation and role in cancer

Seminars in Cell and Developmental Biology

Volumn 43, Issue , 2015, Pages 43-51

  Israelsen, William J ^a,c,d   Vander Heiden, Matthew G ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cancer metabolism; PKM2; Pyruvate kinase

Indexed keywords

LACTIC ACID; PYRUVATE KINASE; GLUCOSE; ISOPROTEIN;

ALLOSTERISM; ALTERNATIVE RNA SPLICING; CATALYSIS; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SPECIFICITY; FIBROBLAST; GENE MAPPING; HUMAN; INTESTINE EPITHELIUM; INTRACELLULAR SIGNALING; KINETICS; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; TAUTOMERIZATION; TUMOR GROWTH; ANIMAL; CELL CYCLE; GENE EXPRESSION REGULATION; GENETICS; GLYCOLYSIS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; ULTRASTRUCTURE;

ANIMALS; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GLUCOSE; GLYCOLYSIS; HUMANS; NEOPLASMS; PROTEIN ISOFORMS; PYRUVATE KINASE; SIGNAL TRANSDUCTION;

EID: 84948094800     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.08.004     Document Type: Review

References (119)

1. Warburg O.H., Posener K., Negelein E. Über den Stoffwechsel der Carcinomzelle. Biochem. Z. 1924, 152:309-344.
2. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
3. Crabtree H.G. Observations on the carbohydrate metabolism of tumours. Biochem. J. 1929, 23:536-545.
4. Eigenbrodt E., Glossmann H. Glycolysis - one of the keys to cancer?. Trends Pharmacol. Sci. 1980, 1:240-245.
5. Eigenbrodt E., Reinacher M., Scheefers-Borchel U., Scheefers H., Friis R. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit. Rev. Oncog. 1992, 3:91-115.
6. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 2011, 43:969-980.
7. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
8. Christofk H.R., Vander Heiden M.G., Wu N., Asara J.M., Cantley L.C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452:181-186.
9. Hitosugi T., Kang S., Vander Heiden M.G., Chung T.W., Elf S., Lythgoe K., et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2009, 2:ra73.
10. Lunt S.Y., Muralidhar V., Hosios A.M., Israelsen W.J., Gui D.Y., Newhouse L., et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol. Cell 2015, 57:95-107.
11. Imamura K., Tanaka T. Pyruvate kinase isozymes from rat. Methods Enzymol. 1982, 90(Part E):150-165.
12. Cardenas J.M., Dyson R.D. Mammalian pyruvate kinase hybrid isozymes: tissue distribution and physiological significance. J. Exp. Zool. 1978, 204:361-367.
13. Imamura K., Tanaka T. Multimolecular forms of pyruvate kinase from rat and other mammalian tissues. I. Electrophoretic studies. J. Biochem. 1972, 71:1043-1051.
14. Strandholm J.J., Dyson R.D., Cardenas J.M. Bovine pyruvate kinase isozymes and hybrid isozymes. Electrophoretic studies and tissue distribution. Arch. Biochem. Biophys. 1976, 173:125-131.
15. Netzker R., Greiner E., Eigenbrodt E., Noguchi T., Tanaka T., Brand K. Cell cycle-associated expression of M2-type isozyme of pyruvate kinase in proliferating rat thymocytes. J. Biol. Chem. 1992, 267:6421-6424.
16. Clower C.V., Chatterjee D., Wang Z., Cantley L.C., Vander Heiden M.G., Krainer A.R. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1894-1899.
17. Eigenbrodt E., Leib S., Kramer W., Friis R.R., Schoner W. Structural and kinetic differences between the M2 type pyruvate kinases from lung and various tumors. Biomed. Biochim. Acta 1983, 42:S278-S282.
18. Noguchi T., Inoue H., Tanaka T. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 1986, 261:13807-13812.
19. Takenaka M., Noguchi T., Sadahiro S., Hirai H., Yamada K., Matsuda T., et al. Isolation and characterization of the human pyruvate kinase M gene. Eur. J. Biochem. 1991, 198:101-106.
20. David C.J., Chen M., Assanah M., Canoll P., Manley J.L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
21. Wang Z., Chatterjee D., Jeon H.Y., Akerman M., Vander Heiden M.G., Cantley L.C., et al. Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons. J. Mol. Cell Biol. 2012, 4:79-87.
22. Wang Z., Jeon H.Y., Rigo F., Bennett C.F., Krainer A.R. Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides. Open Biol. 2012, 2:120133.
23. Chen M., David C.J., Manley J.L. Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nat. Struct. Mol. Biol. 2012, 19:346-354.
24. Stammers D.K., Muirhead H. Three-dimensional structure of cat muscle pyruvate kinase at 3-1 A resolution. J. Mol. Biol. 1977, 112:309-316.
25. Muirhead H., Clayden D.A., Barford D., Lorimer C.G., Fothergill-Gilmore L.A., Schiltz E., et al. The structure of cat muscle pyruvate kinase. EMBO J. 1986, 5:475-481.
26. Larsen T.M., Benning M.M., Rayment I., Reed G.H. Structure of the bis(Mg2+)-ATP-oxalate complex of the rabbit muscle pyruvate kinase at 2.1Å resolution: ATP binding over a barrel. Biochemistry 1998, 37:6247-6255.
27. Dombrauckas J.D., Santarsiero B.D., Mesecar A.D. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44:9417-9429.
28. Jurica M.S., Mesecar A., Heath P.J., Shi W., Nowak T., Stoddard B.L. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure 1998, 6:195-210.
29. Cottam G.L., Hollenberg P.F., Coon M.J. Subunit structure of rabbit muscle pyruvate kinase. J. Biol. Chem. 1969, 244:1481-1486.
30. Ashizawa K., McPhie P., Lin K.H., Cheng S.Y. An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1, 6-bisphosphate. Biochemistry 1991, 30:7105-7111.
31. Mazurek S., Grimm H., Boschek C.B., Vaupel P., Eigenbrodt E. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br. J. Nutr. 2002, 87(Suppl. 1):S23-S29.
32. Gupta R.K., Oesterling R.M. Dual divalent cation requirement for activation of pyruvate kinase; essential roles of both enzyme- and nucleotide-bound metal ions. Biochemistry 1976, 15:2881-2887.
33. Bollenbach T.J., Mesecar A.D., Nowak T. Role of lysine 240 in the mechanism of yeast pyruvate kinase catalysis. Biochemistry 1999, 38:9137-9145.
34. Luo W., Hu H., Chang R., Zhong J., Knabel M., O'Meally R., et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011, 145:732-744.
35. Sakai H. Mutagenesis of the active site lysine 221 of the pyruvate kinase from Bacillus stearothermophilus. J. Biochem. 2005, 137:141-145.
36. Seeholzer S.H., Jaworowski A., Rose I.A. Enolpyruvate: chemical determination as a pyruvate kinase intermediate. Biochemistry 1991, 30:727-732.
37. Susan-Resiga D., Nowak T. Proton donor in yeast pyruvate kinase: chemical and kinetic properties of the active site Thr 298 to Cys mutant. Biochemistry 2004, 43:15230-15245.
38. Susan-Resiga D., Nowak T. The proton transfer step catalyzed by yeast pyruvate kinase. J. Biol. Chem. 2003, 278:12660-12671.
39. Ainsworth S., MacFarlane N. A kinetic study of rabbit muscle pyruvate kinase. Biochem. J. 1973, 131:223-236.
40. Plowman K.M., Krall A.R. A kinetic study of nucleotide interactions with pyruvate kinase. Biochemistry 1965, 4:2809-2814.
41. Hohnadel D.C., Cooper C. The effect of structural alterations on the reactivity of the nucleotide substrate of rabbit muscle pyruvate kinase. FEBS Lett. 1973, 30:18-20.
42. Mazurek S., Grimm H., Wilker S., Leib S., Eigenbrodt E. Metabolic characteristics of different malignant cancer cell lines. Anticancer Res. 1998, 18:3275-3282.
43. Morgan H.P., O'Reilly F.J., Wear M.A., O'Neill J.R., Fothergill-Gilmore L.A., Hupp T., et al. M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5881-5886.
44. Akhtar K., Gupta V., Koul A., Alam N., Bhat R., Bamezai R.N. Differential behavior of missense mutations in the intersubunit contact domain of the human pyruvate kinase M2 isozyme. J. Biol. Chem. 2009, 284:11971-11981.
45. Berglund L., Humble E. Kinetic properties of pig pyruvate kinases type A from kidney and type M from muscle. Arch. Biochem. Biophys. 1979, 195:347-361.
46. Bücher T., Pfleiderer G. Pyruvate kinase from muscle: pyruvate phosphokinase, pyruvic phosphoferase, phosphopyruvate transphosphorylase, phosphate-transferring enzyme II, etc. Phosphoenolpyruvate+ADP⇌Pyruvate+ATP. Methods Enzymol. 1955, 1:435-440.
47. Cardenas J.M., Blachly E.G., Ceccotti P.L., Dyson R.D. Properties of chicken skeletal muscle pyruvate kinase and a proposal for its evolutionary relationship to the other avian and mammalian isozymes. Biochemistry 1975, 14:2247-2252.
48. Cardenas J.M., Dyson R.D. Bovine pyruvate kinases. II. Purification of the liver isozyme and its hybridization with skeletal muscle pyruvate kinase. J. Biol. Chem. 1973, 248:6938-6944.
49. Cardenas J.M., Dyson R.D., Strandholm J.J. Bovine pyruvate kinases. I. Purification and characterization of the skeletal muscle isozyme. J. Biol. Chem. 1973, 248:6931-6937.
50. Hubbard D.R., Cardenas J.M. Kinetic properties of pyruvate kinase hybrids formed with native type L and inactivated type M subunits. J. Biol. Chem. 1975, 250:4931-4936.
51. Ibsen K.H., Chiu R.H., Park H.R., Sanders D.A., Roy S., Garratt K.N., et al. Purification and properties of mouse pyruvate kinases K and M and of a modified K subunit. Biochemistry 1981, 20:1497-1506.
52. Ikeda Y., Tanaka T., Noguchi T. Conversion of non-allosteric pyruvate kinase isozyme into an allosteric enzyme by a single amino acid substitution. J. Biol. Chem. 1997, 272:20495-20501.
53. Imamura K., Taniuchi K., Tanaka T. Multimolecular forms of pyruvate kinase. II. Purification of M2-type pyruvate kinase from Yoshida ascites hepatoma 130 cells and comparative studies on the enzymological and immunological properties of the three types of pyruvate kinases, L, M1, and M2. J. Biochem. 1972, 72:1001-1015.
54. Strandholm J.J., Cardenas J.M., Dyson R.D. Pyruvate kinase isozymes in adult and fetal tissues of chicken. Biochemistry 1975, 14:2242-2246.
55. Tanaka T., Harano Y., Sue F., Morimura H. Crystallization, characterization and metabolic regulation of two types of pyruvate kinase isolated from rat tissues. J. Biochem. 1967, 62:71-91.
56. Taylor C.B., Bailey E. Activation of liver pyruvate kinase by fructose 1,6-diphosphate. Biochem. J. 1967, 102:32C-33C.
57. Cardenas J.M. Pyruvate kinase from bovine muscle liver. Methods Enzymol. 1982, 90(Part E):140-149.
58. Kahn A., Marie J. Pyruvate kinases from human erythrocytes liver. Methods Enzymol. 1982, 90(Part E):131-140.
59. Koler R.D., Vanbellinghen P. The mechanism of precursor modulation of human pyruvate kinase I by fructose diphosphate. Adv. Enzyme Regul. 1968, 6:127-142.
60. Carminatti H., Jimenez de Asua L., Leiderman B., Rozengurt E. Allosteric properties of skeletal muscle pyruvate kinase. J. Biol. Chem. 1971, 246:7284-7288.
61. Vijayvargiya R., Schwark W.S., Singhal R.L. Pyruvate kinase: modulation by l-phenylalanine and l-alanine. Can. J. Biochem. 1969, 47:895-898.
62. Weber G. Inhibition of human brain pyruvate kinase and hexokinase by phenylalanine and phenylpyruvate: possible relevance to phenylketonuric brain damage. Proc. Natl. Acad. Sci. U. S. A. 1969, 63:1365-1369.
63. Williams R., Holyoak T., McDonald G., Gui C., Fenton A.W. Differentiating a ligand's chemical requirements for allosteric interactions from those for protein binding. Phenylalanine inhibition of pyruvate kinase. Biochemistry 2006, 45:5421-5429.
64. Kung C., Hixon J., Choe S., Marks K., Gross S., Murphy E., et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol. 2012, 19:1187-1198.
65. Consler T.G., Lee J.C. Domain interaction in rabbit muscle pyruvate kinase. I. Effects of ligands on protein denaturation induced by guanidine hydrochloride. J. Biol. Chem. 1988, 263:2787-2793.
66. Schulz J., Sparmann G., Hofmann E. Alanine-mediated reversible inactivation of tumour pyruvate kinase caused by a tetramer-dimer transition. FEBS Lett. 1975, 50:346-350.
67. Sparmann G., Schulz J., Hofmann E. Effects of l-alanine and fructose (1,6-diphosphate) on pyruvate kinase from ehrlich ascites tumour cells. FEBS Lett. 1973, 36:305-308.
68. Ibsen K.H., Marles S.W. Inhibition of chicken pyruvate kinases by amino acids. Biochemistry 1976, 15:1073-1079.
69. Chaneton B., Hillmann P., Zheng L., Martin A.C., Maddocks O.D., Chokkathukalam A., et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012, 491:458-462.
70. Fanjul A.N., Farias R.N. Cold-sensitive cytosolic 3,5,3'-triiodo-l-thyronine-binding protein and pyruvate kinase from human erythrocytes share similar regulatory properties of hormone binding by glycolytic intermediates. J. Biol. Chem. 1993, 268:175-179.
71. Keller K.E., Tan I.S., Lee Y.S. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. Science 2012, 338:1069-1072.
72. Keller K.E., Doctor Z.M., Dwyer Z.W., Lee Y.S. SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. Mol. Cell 2014, 53:700-709.
73. Yang W., Zheng Y., Xia Y., Ji H., Chen X., Guo F., et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 2012, 14:1295-1304.
74. Boxer M.B., Jiang J.K., Vander Heiden M.G., Shen M., Skoumbourdis A.P., Southall N., et al. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem. 2010, 53:1048-1055.
75. Jiang J.K., Boxer M.B., Vander Heiden M.G., Shen M., Skoumbourdis A.P., Southall N., et al. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 2010, 20:3387-3393.
76. Parnell K.M., Foulks J.M., Nix R.N., Clifford A., Bullough J., Luo B., et al. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol. Cancer Ther. 2013, 12:1453-1460.
77. Walsh M.J., Brimacombe K.R., Veith H., Bougie J.M., Daniel T., Leister W., et al. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 2011, 21:6322-6327.
78. Anastasiou D., Yu Y., Israelsen W.J., Jiang J.K., Boxer M.B., Hong B.S., et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 2012, 8:839-847.
79. Bond C.J., Jurica M.S., Mesecar A., Stoddard B.L. Determinants of allosteric activation of yeast pyruvate kinase and identification of novel effectors using computational screening. Biochemistry 2000, 39:15333-15343.
80. Reed G.H., Morgan S.D. Kinetic and magnetic resonance studies of the interaction of oxalate with pyruvate kinase. Biochemistry 1974, 13:3537-3541.
81. Varghese B., Swaminathan G., Plotnikov A., Tzimas C., Yang N., Rui H., et al. Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation. Mol. Endocrinol. 2010, 24:2356-2365.
82. Allali-Hassani A., Wasney G.A., Chau I., Hong B.S., Senisterra G., Loppnau P., et al. A survey of proteins encoded by non-synonymous single nucleotide polymorphisms reveals a significant fraction with altered stability and activity. Biochem. J. 2009, 424:15-26.
83. Srivastava D.K., Bernhard S.A. Metabolite transfer via enzyme-enzyme complexes. Science 1986, 234:1081-1086.
84. Srivastava D.K., Bernhard S.A. Enzyme-enzyme interactions and the regulation of metabolic reaction pathways. Curr. Top. Cell. Regul. 1986, 28:1-68.
85. Lv L., Li D., Zhao D., Lin R., Chu Y., Zhang H., et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol. Cell 2011, 42:719-730.
86. Lv L., Xu Y.P., Zhao D., Li F.L., Wang W., Sasaki N., et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol. Cell 2013, 52:340-352.
87. Anastasiou D., Poulogiannis G., Asara J.M., Boxer M.B., Jiang J.K., Shen M., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334:1278-1283.
88. Lunt S.Y., Vander Heiden M.G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 2011, 27:441-464.
89. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
90. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
91. Board M., Humm S., Newsholme E.A. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem. J. 1990, 265:503-509.
92. Heinrich R., Rapoport T.A. A linear steady-state treatment of enzymatic chains. General properties, control and effector strength. Eur. J. Biochem. 1974, 42:89-95.
93. Heinrich R., Rapoport T.A. A linear steady-state treatment of enzymatic chains. Critique of the crossover theorem and a general procedure to identify interaction sites with an effector. Eur. J. Biochem. 1974, 42:97-105.
94. Kacser H., Burns J.A. The control of flux. Symp. Soc. Exp. Biol. 1973, 27:65-104.
95. Ye J., Mancuso A., Tong X., Ward P.S., Fan J., Rabinowitz J.D., et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:6904-6909.
96. Israelsen W.J., Dayton T.L., Davidson S.M., Fiske B.P., Hosios A.M., Bellinger G., et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013, 155:397-409.
97. Wang Y.H., Israelsen W.J., Lee D., Yu V.W., Jeanson N.T., Clish C.B., et al. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell 2014, 158:1309-1323.
98. Cortes-Cros M., Hemmerlin C., Ferretti S., Zhang J., Gounarides J.S., Yin H., et al. M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:489-494.
99. Gao X., Wang H., Yang J.J., Liu X., Liu Z.R. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 2012, 45:598-609.
100. Yang W., Xia Y., Hawke D., Li X., Liang J., Xing D., et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012, 150:685-696.
101. Jiang Y., Li X., Yang W., Hawke D.H., Zheng Y., Xia Y., et al. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol. Cell 2014, 53:75-87.
102. Jiang Y., Wang Y., Wang T., Hawke D.H., Zheng Y., Li X., et al. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells. Nat. Commun. 2014, 5:5566.
103. Hosios A.M., Fiske B.P., Gui D.Y., Vander Heiden M.G. Lack of evidence for PKM2 protein kinase activity. Mol. Cell 2015, 10.1016/j.molcel.2015.07.013.
104. Kundig W., Ghosh S., Roseman S. Phosphate bound to histidine in a protein as an intermediate in a novel phospho-transferase system. Proc. Natl. Acad. Sci. U. S. A. 1964, 52:1067-1074.
105. Postma P.W., Lengeler J.W. Phosphoenolpyruvate: carbohydrate phosphotransferase system of bacteria. Microbiol. Rev. 1985, 49:232-269.
106. Wu L.F., Saier M.H. On the evolutionary origins of the bacterial phosphoenolpyruvate:sugar phosphotransferase system. Mol. Microbiol. 1990, 4:1219-1222.
107. Liao D.I., Silverton E., Seok Y.J., Lee B.R., Peterkofsky A., Davies D.R. The first step in sugar transport: crystal structure of the amino terminal domain of enzyme I of the E. coli PEP: sugar phosphotransferase system and a model of the phosphotransfer complex with HPr. Structure 1996, 4:861-872.
108. Gao X., Wang H., Yang J.J., Chen J., Jie J., Li L., et al. Reciprocal regulation of protein kinase and pyruvate kinase activities of pyruvate kinase M2 by growth signals. J. Biol. Chem. 2013, 288:15971-15979.
109. Palsson-McDermott E.M., Curtis A.M., Goel G., Lauterbach M.A., Sheedy F.J., Gleeson L.E., et al. Pyruvate Kinase M2 Regulates Hif-1alpha Activity and IL-1beta Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages. Cell Metab. 2015, 21:65-80.
110. Lee J., Kim H.K., Han Y.M., Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 2008, 40:1043-1054.
111. Mor I., Carlessi R., Ast T., Feinstein E., Kimchi A. Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase. Oncogene 2012, 31:683-693.
112. Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011, 480:118-122.
113. Simon M., Spahr P.F., Dainous F. The proteins associated with the soluble form of p36, the main target of the src oncogene product in chicken fibroblasts, are glycolytic enzymes. Biochem. Cell Biol. 1989, 67:740-748.
114. Mazurek S., Hugo F., Failing K., Eigenbrodt E. Studies on associations of glycolytic and glutaminolytic enzymes in MCF-7 cells: role of P36. J. Cell Physiol. 1996, 167:238-250.
115. Mendes P., Kell D.B., Welch G.R. Metabolic channeling in organized enzyme systems: experiments and models. Adv. Mol. Cell Biol. 1995, 11:1-19.
116. Johnson F.M., Chasalow F., Anderson G., Macdougal P., Hendren R.W., Lewis S.E. A variation in mouse kidney pyruvate kinase activity determined by a mutant gene on chromosome 9. Genet. Res. 1981, 37:123-131.
117. Peters J., Andrews S.J. The Pk-3 gene determines both the heart, M1, and the kidney, M2, pyruvate kinase isozymes in the mouse; and a simple electrophoretic method for separating phosphoglucomutase-3. Biochem. Genet. 1984, 22:1047-1063.
118. Lewis S.E., Johnson F.M. Dominant and recessive effects of electrophoretically detected specific locus mutations. Utilization of Mammalian Specific Locus Studies in Hazard Evaluation and Estimation of Genetic Risk 1983, 267-278. Plenum Press, New York. F.J. de Serres, W. Sheridan (Eds.).
119. Vander Heiden M.G., Locasale J.W., Swanson K.D., Sharfi H., Heffron G.J., Amador-Noguez D., et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010, 329:1492-1499.